Lenti-vpr TCR (HIV-A2-AL9)-VP (VP-TCR-C578)

The ready-to-use lentiviral particles of Lenti-vpr TCR (HIV-A2-AL9)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


  • Type of Therapeutics
  • T cell receptor
  • Target
  • vpr
  • Clone
  • HIV-A2-AL9
  • Promotor
  • CMV
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • HIV infection


  • Introduction
  • HIV1 p15(Gag) and its protease cleavage products, nucleocapsid protein p7 and p6, are believed to play a major role in viral infectivity and assembly during the early and late stages of retroviral life cycle. p15 is frequently recognized by HIV1-specific CD8+T cells in natural HIV1 infection and may be an important target for the design of future HIV1 vaccines.
  • Alternative Names
  • vpr

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.